Rare Disease Treatment Market Scope
A rare disease is a group of conditions that affect very small numbers of people. Rare diseases affect approximately 6-10% of the population and 3-4% of births. It tends to be severe, chronic conditions and in many cases, they are progressive, debilitating, and life-threatening. Patient access to the treatment, including medicines, is access to healthcare professionals and a healthcare infrastructure that fosters the correct diagnosis. On average, a treatment for a rare disease costs USD137,000 per person per year. According to the WHO, rare diseases range from cystic fibrosis and haemophilia to angelman syndrome, with an incidence of about 1 in 15 000, to Opitz trigonocephaly syndrome. It is extremely rare with about one case per million people. Most people suffering from rare diseases do not have any treatment options available for their condition. (It is estimated that 95% of rare diseases do not have a treatment option.) In March 2020, FDA grants experimental coronavirus drug benefits for rare disease treatments.
The market study is segmented, by Application (Hospitals, Clinics and Others) and major geographies with country level break-up.
Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Rare Disease Treatment market throughout the predicted period.
Novartis (Switzerland), Pfizer, Inc. (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Celgene Corporation (United States), Alexion Pharmaceuticals, Inc. (United States), Johnson & Johnson (United States), Novo Nordisk A/S (Denmark), Sanofi S.A. (France), Bayer AG (Germany), GlaxoSmithKline (United Kingdom), Allergan (Ireland), Eli Lilly and Company (United States), Eisai Co., Ltd. (Japan), Bristol-Myers Squibb and Merck & Co., Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Bristol-Myers Squibb Company (United States), AstraZeneca (United Kingdom), Daiichi Sankyo Company Limited (Japan), Biogen, Inc. (United States), Shire Plc (United States), Alexion Pharmaceuticals (United States), Amgen Inc. (United States), Vertex Pharmaceuticals (United States), Baxter International Inc.. (United States), BioMarin (United States) and Teva Pharmaceutical Industries (Isreal).
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.
AdvanceMarketAnalytics has segmented the market of Global Rare Disease Treatment market by Type, Application and Region.
On the basis of geography, the market of Rare Disease Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
Market Leaders and their expansionary development strategies
In Feb 2019, Ipsen announced the acquisition of the Clementia Pharmaceuticals for the treatment of the key late-stage clinical asset palovarotene, multiple osteochondromas, and others. Through this agreement, the company is aiming to enhance its product portfolio in rare diseases across the globe.
- Growing Research Activities and the Increasing focus on the Development of New Therapeutics and Drugs
- Sustainable Access to Diagnosis, Treatment
- and Care
- Increasing Geriatric Population and the Rising Focus of the Players on the Enhancement of the Medical Facilities
- Rising Awareness among People about Efficient Treatment Methods to Treat Rare Diseases
- Greater Collaboration at all Levels Will Help Drive Research
- and Improve Care
- Rising Investment of Research and Development on the Rare Disease Treatments
- Delays and Frequent Errors in Diagnosis, often with Severe Consequences for Patient Outcomes
- Rare diseases pose challenges for research and clinical development due to the small numbers of patients, limited epidemiological data on the natural history of many rare diseases, and all stages of research and development being more challenging and lengthy than for more
- common diseases.
- Lack of Skilled Healthcare Personnel
Key Target AudienceVenture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Rare Disease Drug Manufacturers, Suppliers and Distributors, Raw Material Suppliers, Government Regulatory and Research Organizations and End-Use Industries
Customization available in this Study:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase